(New York, NY, Tuesday, June 2, 2020) – JDRF is the leading global organization funding type 1 diabetes (T1D) research. The nonprofit organization focuses on accelerating life-changing breakthroughs to cure, prevent, and treat T1D. Since 1970, JDRF has committed more than $2 billion in cumulative research funding to move closer to this goal and to do the greatest good, for the largest number of people, in the shortest period of time.
Insulin is a lifesaving drug for the 1.6 million Americans with T1D who are dependent on injected or pumped insulin to manage their blood-glucose levels. Access to insulin is a matter of life and death, yet insulin costs have soared, and people with T1D incur almost three times the level of medical expenses compared to people without diabetes.
It is absolutely crucial that all people with T1D have affordable access to insulin, meaning it should be available at a low, predictable out-of-pocket cost. JDRF also believes people with T1D should have access to the insulins that work best for them.
JDRF has been fighting for choice not only of insulin, but also choice of insulins pumps, continuous glucose monitors, and artificial pancreas systems, to enable people with T1D to access the technologies that work best for them.
JDRF advocates across the country are also calling on Congress to pass a multi-year renewal of the SDP, a critical program that provides $150 million annually for T1D research at the NIH.